SCHEMBL31368552

SCHEMBL31368552

CC[C@H]1CNCCC(=O)N1CCO

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26744923 0.78 PER2 (0.41) BRD4
SCHEMBL26744978 0.78 PER2 (0.41) BRD4
SCHEMBL3429403 0.70 KMT2A (0.32) BRD4
SCHEMBL9559747 0.68 TAAR1 (0.37)
SCHEMBL1712652 0.67 PDK2 (0.39) BRD4
SCHEMBL1712650 0.66 PDK2 (0.39) BRD4
SCHEMBL14270966 0.66 POLB (0.37) BRD4
SCHEMBL10543893 0.66 KMT2A (0.35)
SCHEMBL4338414 0.64 CHRM2 (0.47) BRD4
SCHEMBL14839577 0.64 PTGER4 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739685-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008061-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed